Autenrieth Jonas, Hedbom Daniel, Strømme Maria, Kipping Thomas, Lindh Jonas, Quodbach Julian
Division of Molecular Pharmaceutics, Department of Pharmacy, Uppsala University, Uppsala Biomedical Center, P.O Box 580, SE-751 23 Uppsala, Sweden.
Division of Nanotechnology and Functional Materials, Department of Materials Science and Engineering, Uppsala University, Ångström Laboratory, Regementsvägen 1, Uppsala 751 03, Sweden.
Int J Pharm X. 2025 May 21;9:100338. doi: 10.1016/j.ijpx.2025.100338. eCollection 2025 Jun.
Selective Laser Sintering (SLS) is an emerging additive manufacturing technology with potential for the production of personalized pharmaceuticals. In this study, we investigated a novel simplified formulation approach in SLS-based manufacturing of individually dosed, multi-layered tablets with distinct layers of pure active pharmaceutical ingredient (API) and excipient. Indomethacin (IND) was chosen as the model API, and polyvinyl alcohol (PVA) served as the excipient. Unlike conventional methods requiring powder blending, this approach utilizes separate powder tanks for IND and PVA, enabling direct printing of alternating layers in a single-step procedure. We successfully fabricated tablets with controlled IND doses by varying the number of IND layers, maintaining consistent printing parameters across different compositions and confirming the API's chemical stability in the product. Since SLS is conventionally used for thermoplastic substances, the successful sintering of pure IND layers was a key achievement in the study, as this crystalline API is typically not printable separately. Energy dispersive X-ray spectroscopy (EDS) demonstrated the successful formation of distinct API and excipient layers. Differential scanning calorimetry (DSC) characterization revealed that the sintering process partially amorphized IND, which may enhance dissolution and bioavailability. Dissolution testing indicated that the printed tablets exhibited improved dissolution rates compared to raw IND powder. The study successfully demonstrated the possibility of SLS-based production for personalized dosing by omitting powder blending steps. The ability to create individualized dosages with minimal excipients and simplified processing represents a step toward further investigation of SLS for clinical settings, including hospital and pharmacy-based drug production.
选择性激光烧结(SLS)是一种新兴的增材制造技术,具有生产个性化药物的潜力。在本研究中,我们研究了一种新颖的简化配方方法,用于基于SLS制造单独给药的多层片剂,该片剂具有不同的纯活性药物成分(API)层和辅料层。选择吲哚美辛(IND)作为模型API,聚乙烯醇(PVA)作为辅料。与需要粉末混合的传统方法不同,该方法为IND和PVA使用单独的粉末罐,能够在单一步骤中直接打印交替层。我们通过改变IND层的数量成功制造了具有可控IND剂量的片剂,在不同组成中保持一致的打印参数,并确认了产品中API的化学稳定性。由于SLS传统上用于热塑性物质,纯IND层的成功烧结是该研究的一项关键成果,因为这种结晶API通常不能单独打印。能量色散X射线光谱(EDS)证明了不同的API层和辅料层的成功形成。差示扫描量热法(DSC)表征显示烧结过程使IND部分非晶化,这可能会提高溶解度和生物利用度。溶出度测试表明,与未加工的IND粉末相比,打印片剂的溶出速率有所提高。该研究成功证明了通过省略粉末混合步骤基于SLS生产个性化剂量的可能性。以最少的辅料和简化的工艺创建个性化剂量的能力代表了朝着进一步研究SLS用于临床环境(包括医院和药房的药物生产)迈出的一步。